Clinical Trial Update: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) [Phase 2]

View source ↗

Summary

Phase 2 trial of MCS110 in pigmented villonodular synovitis (PVNS) has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gccts
• Gcts
• Giant Cell Tumor of the Tendon Sheath
• Pigmented Villonodular Synovitis
• Tenosynovial Giant Cell Tumor Localized or Diffused Type

Drugs mentioned

• MCS110

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pigmented Villonodular Synovitis, PVNS | Phase 2 | Status: COMPLETED | Results posted: 2020-02-27